Skip to main content
SpringerLink
Log in
Book cover

Approaches to Breast Cancer Prevention pp 149–168Cite as

Protection by Progestagens or Antioestrogens

  • Chapter

  • 46 Accesses

Part of the book series: Developments in Oncology ((DION,volume 62))

Abstract

There is considerable clinical evidence that administration of either antioestrogens or progestagens can cause complete or partial tumour regression in advanced breast cancer, both in premenopausal and postmenopausal women. This ability to inhibit the growth of breast cancer in the absence of significant side effects has led some to advocate prolonged continuous administration of these agents to women thought to be at high risk to the disease. It is hypothesised that the clinical manifestation of occult breast cancer will be postponed in a proportion of cases and it may also delay the premalignant phase from progressing to fully invasive cancer.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Powles, T.J., Hardy, J.R., Ashley, S.E. et al. (1989). A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br. J. Cancer, 60,126–131.

    Article  PubMed  CAS  Google Scholar 

  2. Stoll, B.A. (1989). Can oral contraceptives reduce breast cancer risk. In Stoll, B.A. (ed.), Women at High Risk to Breast Cancer, Kluwer, Dordrecht, 85–94.

    Chapter  Google Scholar 

  3. Lemon, H.M. (1987). Antimammary carcinogenic activity of estriol. Cancer, 60, 2873–2881.

    Article  PubMed  CAS  Google Scholar 

  4. Berenblum, J. (1984). Two stage carcinogenesis and multiple cancers. In Stoll, B.A. (ed.), Risk Factors and Multiple Cancer, John Wiley, Chichester, 3–12.

    Google Scholar 

  5. Cowan, L.D., Gordis, L., Tonascia, J.A. et al. (1981). Breast cancer incidence in women with a history of progesterone deficiency. Am. J. Epidemiol., 144, 209–213.

    Google Scholar 

  6. Coulan, C.B., Annergers, J.F. (1983). Chronic anovulation may increase postmenopausal breast cancer risk. J. Am. Med. Assoc., 249, 445–447.

    Article  Google Scholar 

  7. Henderson, B.E., Ross, R., Bernstein, L. (1988). Estrogens as a cause of human cancer. Cancer Res.,48, 246–253.

    PubMed  CAS  Google Scholar 

  8. Potten, C.S., Watson, R.J., Williams, G.T. et al. (1988). The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br. J. Cancer, 58, 163–170.

    Article  PubMed  CAS  Google Scholar 

  9. Anderson, T.J. (1986). Effects on breast tissue of exogenous oestrogens and progestogens. Acta Obstet. Gynecol. Scand. (Suppl.), 134, 9–13.

    Article  CAS  Google Scholar 

  10. Pike, M.C. (1985). Breast cancer and oral contraceptives. Lancet, ii, 1180–1181.

    Article  Google Scholar 

  11. Gompel, A., Malet, C., Spritzen, P. et al. (1986) Progestin effect on cell proliferation and 17β deydrogenase activity in normal human breast cells in culture. J. Clin. Endocrinol. Metab., 63, 1174–1180.

    Article  PubMed  CAS  Google Scholar 

  12. Meyer, J.S. (1977). Cell proliferation in normal human breast ducts, fibroadenomas and other ductal hyperplasias measured by nuclear labelling with tritiated thymidine. Human Pathol., 8, 67–81.

    Article  CAS  Google Scholar 

  13. Fechner, R.E. (1977). Influence of oral contraceptives on breast disease. Cancer, 39, 2764–2769.

    Article  PubMed  CAS  Google Scholar 

  14. Gill, P.G., Vignon, F., Bardon, S. et al. (1987). Difference between R 5020 and the antiprogestin RU 486 in antiproliferative effects on human breast cancer cells. Breast Cancer Res. Treat., 10, 37–45.

    Article  PubMed  CAS  Google Scholar 

  15. Vignon, F., Bardon, S., Dhalbos, D., Rochefort, H. (1983). Antiestrogenic effect of R 5020, a synthetic progestin, in human breast cancer cells in culture. J. Clin. Endocrinol. Metab., 56, 1124–1130.

    Article  PubMed  CAS  Google Scholar 

  16. Allegra, J.C., Kiefer, S.M. (1985). Mechanisms of action of progestational agents. Semin. Oncol., 12 (Suppl. 1), 3–5.

    PubMed  CAS  Google Scholar 

  17. Horwitz, K.B. (1985). Progestins inhibit growth and increase insulin receptors in antiestrogen-resistant T-47D human breast cancer cells; implications for endocrine therapies. Cancer Res., 45, 167–173.

    PubMed  CAS  Google Scholar 

  18. Klijn, J.G.M., de Jong, F.H., Bakker, G.H. et al. (1989). Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res., 49, 2851–2856.

    PubMed  CAS  Google Scholar 

  19. Murphy, L.C., Dotzlaw, H. (1989). Endogenous growth factor expression in T47D human breast cancer cells, associated with reduced sensitivity to antiproliferative effects of progestins and antiestrogens. Cancer Res., 49, 599–604.

    PubMed  CAS  Google Scholar 

  20. Longman, S.M., Buehring, G.C. (1987). Oral contraceptives and breast cancer; in vitro effect of contraceptive steroids on human mammary cell growth. Cancer., 59, 281–287.

    Article  PubMed  CAS  Google Scholar 

  21. McManus, M.J., Welsch, C.W. (1984). The effect of estrogen, progesterone, thyroxine and HPL on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer, 54, 1920–1927.

    Article  PubMed  CAS  Google Scholar 

  22. Thomas, D.B. (1988). Steroid hormones and medications that alter cancer risks. Cancer, 62, 1755–1767.

    Article  PubMed  CAS  Google Scholar 

  23. Rowe, J.M., Friesen, H.G. (1984). Growth factors, hormones, oncogenes and cancer. Rev. Endocrin. Rel. Cancer, 18, 27–35.

    Google Scholar 

  24. Sainsbury, J.R.C. (1988). Growth factors and their receptors as mediators of response. In Stoll, B.A. (ed.), Endocrine Management of Cancer; Biological Bases, Karger, Basel, 35–44.

    Google Scholar 

  25. Buzdar, A.U. (1988). Progestins in cancer treatment. In Stoll, B.A. (ed.), Endocrine Management of Cancer: Contemporary Therapy, Karger, Basel, 1–15.

    Google Scholar 

  26. Kennedy, B.J. (1965). Hormone therapy for advanced breast cancer. Cancer, 18, 1551–1557.

    Article  PubMed  CAS  Google Scholar 

  27. Landau, R.L., Ehrlich, E.N., Huggins, C. (1962). Estradiol benzoate and progesterone in advanced human mammary cancer. J. Am. Med. Assoc., 182, 632–636.

    Article  Google Scholar 

  28. Berndt, G. (1970). Management of metastasising mammary carcinoma with oestrogen-gestagen combination therapy by SH 834. Dtch. Med. Wochschr., 95, 2399–2404.

    Article  CAS  Google Scholar 

  29. Stoll, B.A. (1967). Vaginal cytology as an aid to hormone therapy in postmenopausal breast cancer. Cancer, 20, 1807–1811.

    Article  PubMed  CAS  Google Scholar 

  30. Stoll, B.A. (1966). Therapy by progestational agents in advanced breast cancer. Med. J. Aust., 1, 331–335.

    PubMed  CAS  Google Scholar 

  31. Muggia, F.M., Cassileth, P.A., Flatow, F.A. et al. (1967). Treatment for breast cancer with medroxyprogesterone. Ann. Intern. Med., 66, 1066–1072.

    Google Scholar 

  32. Chemama, R., Jayle, M.F., Ennuyer, A. (1974). Treatment by oestrogen-progestin-corticosteroid combination in breast cancer. In Stoll, B.A. (ed.), Mammary Cancer and Neuroendocrine Therapy, Butterworth, London, 265–282.

    Google Scholar 

  33. Stoll, B.A. (1967). Effect of Lyndiol, an oral contraceptive, on breast cancer. Br. Med. J., 1, 150–53.

    Article  PubMed  CAS  Google Scholar 

  34. Powles, T.J. (1988). Treatment of menopausal symptoms in breast cancer patients. Lancet, ii, 344–345.

    Article  Google Scholar 

  35. Matthews, P.N., Mills, P.R., Hayward, J.L. (1981). Breast cancer in women who have taken contraceptive steroids. Br. Med. J., 282, 774–776.

    Article  CAS  Google Scholar 

  36. Gambrell, R.D. Jr., Maier, R.C., Sanders, B.I. (1983). Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet. Gynecol., 62, 435–438.

    PubMed  Google Scholar 

  37. Rosner, D., Lane, W.W., Brett, R.P. (1985). Influence of oral contraceptives on the prognosis of breast cancer in young women. Cancer., 55, 1556–1562.

    Article  PubMed  CAS  Google Scholar 

  38. Royal College of General Practitioners (1977). Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet, 1, 624–626.

    Google Scholar 

  39. UK National Case-control Study Group (1989). Oral contraceptive use and breast cancer risk in young women. Lancet i, 973–982.

    Google Scholar 

  40. World Health Organization (1986). Depot medroxyprogesterone acetate and cancer. Bull. WHO, 64, 375–382.

    Google Scholar 

  41. Paul, C., Skegg, D.C.G., Spears, G.F.S. (1989). Depot medroxyprogesterone and risk of breast cancer. Br. Med. J., 299, 759–762.

    Article  CAS  Google Scholar 

  42. Nachtigall, L.E., Nachtigall, R.H., Nachtigall, R.D. et al., (1979). Estrogen replacement: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet. Gynecol., 54, 74–76.

    Article  PubMed  CAS  Google Scholar 

  43. Lauritzen, C., Meier, F. (1984). Risks of endometrial and mammary cancer morbidity and mortality in long-term oestrogen treatment. In Herendael, H. & B., Ripwagen, F.E., Goessens, I., van der Pas, H. (eds.) The Climacteric — an Update, Lancaster, MTP Press, 207–216.

    Chapter  Google Scholar 

  44. Gambrell, R.D. Hormonal medication and mitogenic dangers (1988). In Stoll, B.A. (ed.), Endocrine Management of Cancer; Contemporary Therapy, Karger, Basel, 126–143.

    Google Scholar 

  45. Ewertz, M. (1988). Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int. J. Cancer, 42, 832–838.

    Article  PubMed  CAS  Google Scholar 

  46. De Waard, F., Baanders-yen Halewijn, E.A. (1974). A prospective study on breast cancer risk in postmenopausal women. Int. J. Cancer, 14, 153–160.

    Article  PubMed  Google Scholar 

  47. Key, T.J.A., Pike, M.C. (1988). The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur. J. Cancer Clin. Oncol., 24, 29–43.

    Article  PubMed  CAS  Google Scholar 

  48. Runnenbaum, B., Rabe, T. (1987). New progestagens in oral contraceptives. Am. J. Obstet. Gynecol., 157, 1059–1063.

    Google Scholar 

  49. Chez, R.A. (1989). Clinical aspects of three new progestagens; Desogestrel, gestodene and norgestimate. Am. J. Obstet. Gynecol., 160, 1296–1300.

    PubMed  CAS  Google Scholar 

  50. Baum, M. (1989). Communication. Hospital Doctor, 22, 36.

    Google Scholar 

  51. Walker-Jones, D. (1988). TFGbeta stimulates expression of milk fat globule protein in transformed human mammary epithelial cells. Ann. Meeting Am. Assoc. Cancer Res., New Orleans.

    Google Scholar 

  52. Stoll, B.A., Parbhoo, S. (1988). Treatment of menopausal symptoms in breast cancer patients. Lancet, i, 1278–1279.

    Google Scholar 

  53. Smith, I. (1988). Adjuvant tamoxifen for early breast cancer. Br. J. Cancer, 57, 527–528.

    Article  PubMed  CAS  Google Scholar 

  54. Gazet, J.C. (1985). Tamoxifen prophylaxis for women at high risk of breast cancer. Lancet, ii, 1119.

    Article  Google Scholar 

  55. Cuzick, J., Wang, D.Y., Bulbrook, R.D. (1986). The prevention of breast cancer. Lancet, i, 83–86.

    Google Scholar 

  56. Love, R.R. (1990). Prospects for antiestrogen chemoprevention of breast cancer. J. Natl. Cancer Inst., 82, 18–21.

    Article  PubMed  CAS  Google Scholar 

  57. Jordan, V.C. Antiestrogens in cancer treatment (1988). In Stoll, B.A. (ed.), Endocrine Management of Breast Cancer; Contemporary Therapy, Karger, Basel, 57–64.

    Google Scholar 

  58. Diver, J.M.J., Jackson, I.M., Fitzgerald, J.D. (1986). Tamoxifen and non-malignant indications. Lancet, i, 733.

    Google Scholar 

  59. Fentiman, I.S., Powles, T.J. (1987). Tamoxifen and benign breast problems. Lancet, ii, 1070–1072.

    Google Scholar 

  60. Lynch, H.T., Marcus, J.N., Watson, P., Lynch, J.F. (1989). Familial and genetic factors. In Stoll, B. A. (ed.), Women at High Risk to Breast Cancer. Kluwer, Dordrecht, 27–40.

    Chapter  Google Scholar 

  61. Dupont, W.D., Page, D.L. (1985). Risk factors for breast cancer in women with proliferative breast disease. N. Engl. J. Med., 312, 146–151.

    Article  PubMed  CAS  Google Scholar 

  62. Stoll, B.A. (1990). Quantifying the risk of breast cancer. Eur. J. Surg. Oncol., 16, 00–00.

    CAS  Google Scholar 

  63. Simpson, H.W., Mutch, F., Halberg, F. et al. (1982). Bimodal age frequency distribution of epitheliosis in cancer mastectomies. Cancer, 50, 2417–2422.

    Article  PubMed  CAS  Google Scholar 

  64. Simpson, H.W., Candlish, W., Paulson, A.W. et al. (1988). Genesis of breast cancer is in the premenopause. Lancet, ii, 74–76.

    Google Scholar 

  65. Sakai, F., Cheix, F., Clavel, M. et al. (1978). Increase in steroid-binding globulins induced by tamoxifen in patients with breast cancer. J. Endocrinol., 76, 219–225.

    Article  PubMed  CAS  Google Scholar 

  66. Ashford, A.R., Donev, I., Tiwari, R.P., Garrett, T.J. (1988). Reversible ocular toxicity related to tamoxifen therapy. Cancer, 61, 33–35.

    Article  PubMed  CAS  Google Scholar 

  67. Foraander, T., Rutqvist, L.E., Cedermark, B. et al. (1989). Adjuvant tamoxifen in early breast cancer; occurrence of new primary cancers. Lancet, i, 117–120.

    Google Scholar 

  68. Stewart, H.J., Knight, G.M. (1983). Tamoxifen and the uterus and endometrium. Lancet, i, 375.

    Google Scholar 

  69. Gullino, P.M., Grantham, F.H., Losonczy, I., Berghoffer, B. (1972). Mammary tumor regression. Physiopathologic characteristics of hormone-dependent tissue. J. Natl. Cancer Inst., 49, 1333–1348.

    PubMed  CAS  Google Scholar 

  70. Selby, P. (1986). Stem cells and clonogenic assay. In Stoll, B.A. (ed.), Breast Cancer Treatment and Prognosis, Blackwell, London, 312–321.

    Google Scholar 

  71. Hilf, R., Goldenberg, H., Michel, I. et al. (1969). Characteristics of mammary glands and mammary tumours of rats induced by 3MC and DMBA. Cancer Res., 29, 977–985.

    PubMed  CAS  Google Scholar 

  72. Nicholson, R.J., Gotting, K. (1986). Comparative biological and antitumour effects of antioestrogens in the rat. Rev. Endocrin. Rel. Cancer., 19, (Suppl.), 49–62.

    Google Scholar 

  73. Cho-Chung, Y.S. (1988). Models of tumour regression in endocrine-related cancer. In Stoll, B.A. (ed.), Endocrine Management of Cancer-Biological Bases, Karger, Basel, 1–13.

    Google Scholar 

  74. Thompson, E.W., Martin, M.B., Saceda, M. (1989). Regulation of breast cancer cells by hormones and growth factors. Effects on proliferation and basement membrane invasiveness. Horm. Res., (Suppl. 1), 242–249.

    Google Scholar 

  75. Lee, R.W., Buzdar, A.U., Blumenschein, G.R., Hortobagyi, G.N. (1986). Trioxifene mesylate in the treatment of advanced breast cancer. Cancer, 57, 40–43.

    Article  PubMed  CAS  Google Scholar 

  76. Ebbs, S.R., Roberts, J.V., Baum, M. (1987). Alternative mechanisms of action for antioestrogens in breast cancer. Lancet, ii, 621.

    Google Scholar 

  77. Ahlemann, L.M., Heil, M., Staab, H.J. (1987). Droloxifene intermittent therapy in metastatic breast cancer. J. Steroid Biochem., 28, 108S. Abst C030.

    Article  Google Scholar 

  78. Wakeling, A.E. (1989). The potential for a novel pure anti-oestrogen. Horm. Res. (Suppl. 1), 257–260.

    Google Scholar 

  79. Stoll, B.A. (1983). Intermittent antiestrogen therapy in advanced breast cancer. Cancer Treat. Rep., 67, 98.

    PubMed  CAS  Google Scholar 

  80. Costa, A., Veronesi, V., Marubini, E. et al. (1987). Prevention of contralateral breast cancer with Fenretinide. (Abst.) Eur. Congr. Clin. Oncol.

    Google Scholar 

Download references

Authors
  1. Basil A. Stoll
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oncology Department St Thomas’ Hospital, and to Joint Breast Clinic, Royal Free Hospital, London, UK

    Basil A. Stoll FRCR, FFR (Honorary Consulting Physician) (Honorary Consulting Physician)

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Stoll, B.A. (1991). Protection by Progestagens or Antioestrogens. In: Stoll, B.A. (eds) Approaches to Breast Cancer Prevention. Developments in Oncology, vol 62. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-3742-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-3742-3_10

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-5664-9

  • Online ISBN: 978-94-011-3742-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation